Trends in Investigator-Initiated Clinical Studies at a University Hospital after Enforcement of the 2018 Clinical Trials Act in Japan

• Published in: Biological & pharmaceutical bulletin Vol. 45; no. 3; pp. 374 - 377
• Main Authors: Goda, Mitsuhiro, Kane, Chikako, Kubo, Yoshiaki, Nokihara, Hiroshi, Hashimoto, Ichiro, Yagi, Kenta, Sato, Yasutaka, Sakaguchi, Satoshi, Hamano, Hirofumi, Chuma, Masayuki, Takechi, Kenshi, Yanagawa, Hiroaki, Aoe, Yuki
• Format: Journal Article
• Language: English
• Published: Japan The Pharmaceutical Society of Japan 01.03.2022; Japan Science and Technology Agency
• Subjects: clinical research; Clinical trials; Clinical Trials Act; Clinical Trials as Topic - legislation & jurisprudence; Enforcement; Hospitals, University; Humans; investigator; Japan; trend; Japan; investigator; Clinical Trials Act; clinical research; trend; Japan
• ISSN: 0918-6158; 1347-5215; 1347-5215
• DOI: 10.1248/bpb.b21-00753

In April 2018, the Clinical Trials Act pertaining to investigator-initiated clinical trials was passed in Japan. The purpose of this study was to investigate activity in investigator-initiated clinical studies before and after enforcement of the new Clinical Trials Act. This was done by analysing the records of the Ethics Committee of Tokushima University Hospital, which reviews studies based on the Japanese government’s Ethical Guidelines for Medical and Health Research Involving Human Subjects prior to the Clinical Trials Act, and records of the Certified Review Board established at Tokushima University under the Clinical Trials Act in 2018. The number of new applications to these two review boards during fiscal years 2015–2017 (pre-Act) and fiscal years 2018 and 2019 (post-Act) were used as an indicator of activity in investigator-initiated clinical studies. The number of new applications to the Ethics Committee was 303, 261, 316, 303, and 249 in 2015, 2016, 2017, 2018, and 2019, respectively. The data show that the total number of new interventional studies decreased from 50.3 in average in 2015–2017 (pre-Act) to 42 in 2018 and 40 in 2019 (post-Act), respectively. These results suggest that fewer interventional studies were started following enforcement of the new Clinical Trials Act. To confirm this trend and identify contributing factors, further studies are required. In addition, possible way, such as broader contribution of clinical research coordinators, to promote clinical studies in the new Clinical Trials Act era should be examined.